IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v24y2023i6d10.1007_s10198-022-01513-2.html
   My bibliography  Save this article

Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France

Author

Listed:
  • Manon Belhassen

    (PELyon
    Hôpital Européen Georges Pompidou, Université de Paris)

  • Olivier Hanon

    (Université de Paris, APHP Centre, Hôpital Broca)

  • Philippe Gabriel Steg

    (Université de Paris, INSERM U-1148/LVTS, F ; Assistance Publique-Hôpitaux de Paris, Hôpital Bichat)

  • Isabelle Mahé

    (Hôpital Louis Mourier, Université de Paris, Innovative Therapies in Haemostasis, INSERM)

  • Mélanie Née

    (PELyon)

  • Flore Jacoud

    (PELyon)

  • Faustine Dalon

    (PELyon)

  • François-Emery Cotté

    (Bristol-Myers Squibb)

  • Dominique Guitard-Dehoux

    (Bristol-Myers Squibb)

  • Claire Marant-Micallef

    (PELyon)

  • Eric Van Ganse

    (PELyon)

  • Nicolas Danchin

    (Hôpital Européen Georges Pompidou, Université de Paris)

Abstract

Objectives Compare costs associated with all-cause healthcare resource use (HCRU), stroke/systemic thromboembolism (STE) and major bleedings (MB) between patients with non-valvular atrial fibrillation (NVAF) initiating apixaban or other oral anticoagulants (OACs). Methods We performed a retrospective cohort study using the French healthcare claims database, including NVAF patients between 2014/01/01 and 2016/12/31, followed until 2016/12/31. We used 4 sub-cohorts of OAC-naive patients, respectively initiating apixaban, dabigatran, rivaroxaban or VKAs. We matched patients initiating apixaban with patients initiating each other OACs using 1:n propensity score matching. All-cause HCRU and event-related costs by OAC treatment were estimated and compared between matched patients using generalised-linear models with gamma-distribution and two-part models. Results There were 175,766 patients in the apixaban–VKA, 181,809 in the apixaban–rivaroxaban, and 42,490 in the apixaban–dabigatran matched cohorts. Patients initiating apixaban had significantly lower HCRU costs than patients initiating VKA (€1,105 vs. €1,578, p

Suggested Citation

  • Manon Belhassen & Olivier Hanon & Philippe Gabriel Steg & Isabelle Mahé & Mélanie Née & Flore Jacoud & Faustine Dalon & François-Emery Cotté & Dominique Guitard-Dehoux & Claire Marant-Micallef & Eric , 2023. "Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(6), pages 867-875, August.
    • Handle: RePEc:spr:eujhec:v:24:y:2023:i:6:d:10.1007_s10198-022-01513-2
    DOI: 10.1007/s10198-022-01513-2
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-022-01513-2
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s10198-022-01513-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Or., Zeynep, 2014. "Implementation of DRG Payment in France: Issues and recent developments," Health Policy, Elsevier, vol. 117(2), pages 146-150.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jian, Weiyan & Lu, Ming & Liu, Guofeng & Chan, Kit Yee & Poon, Adrienne N., 2019. "Beijing's diagnosis-related group payment reform pilot: Impact on quality of acute myocardial infarction care," Social Science & Medicine, Elsevier, vol. 243(C).
    2. Li Wu & Conghua Ji & Hanti Lu & Xuewen Hong & Shan Liu & Ying Zhang & Qiushuang Li & Sijia Huang & Penglei Zhou & Jiong Yao & Yuxiu Hu, 2018. "Standardization of medical service indicators: A useful technique for hospital administration," PLOS ONE, Public Library of Science, vol. 13(11), pages 1-13, November.
    3. Buczak-Stec, Elżbieta & Goryński, Paweł & Nitsch-Osuch, Aneta & Kanecki, Krzysztof & Tyszko, Piotr, 2017. "The impact of introducing a new hospital financing system (DRGs) in Poland on hospitalisations for atherosclerosis: An interrupted time series analysis (2004–2012)," Health Policy, Elsevier, vol. 121(11), pages 1186-1193.
    4. Milstein, Ricarda & Schreyögg, Jonas, 2024. "The end of an era? Activity-based funding based on diagnosis-related groups: A review of payment reforms in the inpatient sector in 10 high-income countries," Health Policy, Elsevier, vol. 141(C).
    5. Rachet-Jacquet, Laurie & Toulemon, Léa & Rochaix, Lise, 2021. "Hospital payment schemes and high-priced drugs: Evidence from the French Add-on List," Health Policy, Elsevier, vol. 125(7), pages 923-929.
    6. Gautam Gowrisankaran & Keith A. Joiner & Jianjing Lin, 2016. "How do Hospitals Respond to Payment Incentives?," NBER Working Papers 22873, National Bureau of Economic Research, Inc.
    7. Chanturidze, Tata & Esau, Mike & Hölzer, Simon & Richardson, Erica, 2016. "Introducing Diagnosis-Related Groups in Kazakhstan: Evolution, achievements, and challenges," Health Policy, Elsevier, vol. 120(9), pages 987-991.
    8. Meng, Zhaolin & Hui, Wen & Cai, Yuanyi & Liu, Jiazhou & Wu, Huazhang, 2020. "The effects of DRGs-based payment compared with cost-based payment on inpatient healthcare utilization: A systematic review and meta-analysis," Health Policy, Elsevier, vol. 124(4), pages 359-367.
    9. Sutherland, Jason M. & Liu, Guiping & Crump, R. Trafford & Law, Michael, 2016. "Paying for volume: British Columbia’s experiment with funding hospitals based on activity," Health Policy, Elsevier, vol. 120(11), pages 1322-1328.
    10. George Fragkiadakis & Michael Doumpos & Constantin Zopounidis & Christophe Germain, 2016. "Operational and economic efficiency analysis of public hospitals in Greece," Annals of Operations Research, Springer, vol. 247(2), pages 787-806, December.
    11. Zuzana Kotherová & Martina Caithamlová & Juraj Nemec & Kateřina Dolejšová, 2021. "The Use of Diagnosis-Related Group-Based Reimbursement in the Czech Hospital Care System," IJERPH, MDPI, vol. 18(10), pages 1-18, May.
    12. Kreutzberg, Anika & Eckhardt, Helene & Milstein, Ricarda & Busse, Reinhard, 2024. "International strategies, experiences, and payment models to incentivise day surgery," Health Policy, Elsevier, vol. 140(C).
    13. Zeynep Or & Coralie Gandré & George Wharton, 2022. "Soutenabilité et résilience du système de santé français," Working Papers DT88, IRDES institut for research and information in health economics, revised Jun 2022.
    14. Bertezene, Sandra, 2018. "Control of hospitals and nursing homes in France: The 2016 reform may indirectly improve a dysfunctional system," Health Policy, Elsevier, vol. 122(4), pages 329-333.
    15. Field, Robert I. & Keller, Catherine & Louazel, Michel, 2020. "Can governments push providers to collaborate? A comparison of hospital network reforms in France and the United States," Health Policy, Elsevier, vol. 124(10), pages 1100-1107.
    16. Anne Albert-Cromarias & Catherine dos Santos, 2020. "Les paradoxes dans un établissement de santé : reconstruire du sens par l’innovation managériale," Post-Print hal-03024010, HAL.
    17. Helen Hayes & Jonathan Stokes & Matt Sutton & Rachel Meacock, 2024. "How do hospitals respond to payment unbundling for diagnostic imaging of suspected cancer patients?," Health Economics, John Wiley & Sons, Ltd., vol. 33(5), pages 823-843, May.
    18. Omar Al-Khalil & Fabio Valeri & Oliver Senn & Thomas Rosemann & Stefania Di Gangi, 2020. "Effects of a DRG-based hospital reimbursement on the health care utilization and costs in Swiss primary care: A retrospective “quasi-experimental” analysis," PLOS ONE, Public Library of Science, vol. 15(10), pages 1-14, October.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:24:y:2023:i:6:d:10.1007_s10198-022-01513-2. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.